I agree that this site is using cookies. You can find further informations here.
X
Bruscaggin, A.
81  results:
Search for persons X
?
1

Clinical utility of circulating tumor DNA qualification and..:

Pirosa, M. C. ; Bruscaggin, A. ; Terzi di Bergamo, L....
Hematological Oncology.  41 (2023)  S2 - p. 319-321 , 2023
Link: https://doi.org/10.1002/..
 
?
2

MOLECULAR CLUSTERING ON CTDNA IMPROVES THE PROGNOSTIC STRAT..:

Moia, R. ; Talotta, D. ; Dondolin, R....
Hematological Oncology.  41 (2023)  S2 - p. 174-175 , 2023
Link: https://doi.org/10.1002/..
 
?
3

S225: CIRCULATING TUMOR DNA IS A PROGNOSTIC BIOMARKER AT BA..:

Pirosa, M. C. ; Bruscaggin, A. ; Terzi di Bergamo, L....
HemaSphere.  6 (2022)  - p. 126-127 , 2022
Link: https://doi.org/10.1097/..
 
?
4

CIRCULATING TUMOR DNA IS A PROGNOSTIC BIOMARKER IN CLASSIC ..:

Spina, V. ; Pirosa, M. C. ; Bruscaggin, A....
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
5

ADAPTATION OF CHRONIC LYMPHOCYTIC LEUKEMIA TO IBRUTINIB IS ..:

Terzi di Bergamo, L ; Forestieri, G ; Loh, J. W...
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
6

IBRUTINIB TOLERABILITY AND OUTCOME IN PATIENTS WITH HIGH‐RI..:

Condoluci, A. ; Terzi‐di‐Bergamo, L. ; Forestieri, G....
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
7

DISSECTING THE GENETICS OF DIFFERENT ANATOMICAL COMPARTMENT..:

Moia, R. ; Favini, C. ; Ferri, V....
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
8

GENETIC AND PHENOTYPIC ATTRIBUTES OF SPLENIC MARGINAL ZONE ..:

Bonfiglio, F. ; Bruscaggin, A. ; Guidetti, F....
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
9

MULTI‐OMICS LANDSCAPE OF SPLENIC MARGINAL ZONE LYMPHOMA (SM..:

Bruscaggin, A. ; Mollejo, M. ; Tapia, G....
Hematological Oncology.  37 (2019)  S2 - p. 181-182 , 2019
Link: https://doi.org/10.1002/..
 
?
10

Genotyping of Classical Hodgkin Lymphoma on the Liquid Biop..:

Bruscaggin, A. ; Spina, V. ; Di Trani, M....
Hematological Oncology.  35 (2017)  S2 - p. 64-65 , 2017
Link: https://doi.org/10.1002/..
 
?
11

KMT2D AND TP53 MUTATIONS PREDICT POOR PFS AND OS IN MANTLE ..:

Ferrero, S. ; Rossi, D. ; Bruscaggin, A....
Hematological Oncology.  35 (2017)  S2 - p. 94-95 , 2017
Link: https://doi.org/10.1002/..
 
?
12

Targeting CD19-positive lymphomas with the antibody-drug co..:

Tarantelli, Chiara ; Wald, David ; Munz, Nicolas...
Haematologica.  , 2024
Link: https://doi.org/10.3324/..
 
?
13

P597: XPO1 MUTATIONS IDENTIFY EARLY STAGE CLL CHARACTERIZED..:

Talotta, Donatella ; Moia, Riccardo ; Terzi DI Bergamo, Lodovico...
HemaSphere.  7 (2023)  S3 - p. e927804e , 2023
Link: https://doi.org/10.1097/..
 
?
14

Baseline circulating tumour DNA and interim PET predict res..:

Calabretta, Eleonora ; di Trani, Martina ; Corrado, Francesco...
British Journal of Haematology.  204 (2023)  2 - p. 514-524 , 2023
Link: https://doi.org/10.1111/..
 
?
15

XPO1 mutations identify early‐stage CLL characterized by sh..:

Moia, Riccardo ; Terzi di Bergamo, Lodovico ; Talotta, Donatella...
British Journal of Haematology.  203 (2023)  3 - p. 416-425 , 2023
Link: https://doi.org/10.1111/..
 
1-15